Sandbox:Javaria: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
<ref name="pmid22750769">{{cite journal |vauthors=Garg PK, Jain BK, Dubey IB, Sharma AK |title=Generalized lymphadenopathy: physical examination revisited |journal=Ann Saudi Med |volume=33 |issue=3 |pages=298–300 |date=2013 |pmid=22750769 |pmc=6078537 |doi=10.5144/0256-4947.2012.01.7.1525 |url=}}</ref><ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid12484692">{{cite journal |vauthors=Bazemore AW, Smucker DR |title=Lymphadenopathy and malignancy |journal=Am Fam Physician |volume=66 |issue=11 |pages=2103–10 |date=December 2002 |pmid=12484692 |doi= |url=}}</ref><ref name="pmid10549745">{{cite journal |vauthors=Soldes OS, Younger JG, Hirschl RB |title=Predictors of malignancy in childhood peripheral lymphadenopathy |journal=J. Pediatr. Surg. |volume=34 |issue=10 |pages=1447–52 |date=October 1999 |pmid=10549745 |doi=10.1016/s0022-3468(99)90101-x |url=}}</ref><ref name="pmid10189390">{{cite journal |vauthors=Ghirardelli ML, Jemos V, Gobbi PG |title=Diagnostic approach to lymph node enlargement |journal=Haematologica |volume=84 |issue=3 |pages=242–7 |date=March 1999 |pmid=10189390 |doi= |url=}}</ref><ref name="pmid28348622">{{cite journal |vauthors=Ramadas AA, Jose R, Varma B, Chandy ML |title=Cervical lymphadenopathy: Unwinding the hidden truth |journal=Dent Res J (Isfahan) |volume=14 |issue=1 |pages=73–78 |date=2017 |pmid=28348622 |pmc=5356393 |doi=10.4103/1735-3327.201136 |url=}}</ref>
The algorathmn illustrates the approach to management of [[lymphadenopathy]]<ref name="pmid22750769">{{cite journal |vauthors=Garg PK, Jain BK, Dubey IB, Sharma AK |title=Generalized lymphadenopathy: physical examination revisited |journal=Ann Saudi Med |volume=33 |issue=3 |pages=298–300 |date=2013 |pmid=22750769 |pmc=6078537 |doi=10.5144/0256-4947.2012.01.7.1525 |url=}}</ref><ref name="pmid10549745">{{cite journal |vauthors=Soldes OS, Younger JG, Hirschl RB |title=Predictors of malignancy in childhood peripheral lymphadenopathy |journal=J. Pediatr. Surg. |volume=34 |issue=10 |pages=1447–52 |date=October 1999 |pmid=10549745 |doi=10.1016/s0022-3468(99)90101-x |url=}}</ref><ref name="pmid10189390">{{cite journal |vauthors=Ghirardelli ML, Jemos V, Gobbi PG |title=Diagnostic approach to lymph node enlargement |journal=Haematologica |volume=84 |issue=3 |pages=242–7 |date=March 1999 |pmid=10189390 |doi= |url=}}</ref><ref name="pmid28348622">{{cite journal |vauthors=Ramadas AA, Jose R, Varma B, Chandy ML |title=Cervical lymphadenopathy: Unwinding the hidden truth |journal=Dent Res J (Isfahan) |volume=14 |issue=1 |pages=73–78 |date=2017 |pmid=28348622 |pmc=5356393 |doi=10.4103/1735-3327.201136 |url=}}</ref>. Borrowed from:<ref name="pmid24753638">{{cite journal |vauthors=Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A |title=Peripheral lymphadenopathy: approach and diagnostic tools |journal=Iran J Med Sci |volume=39 |issue=2 Suppl |pages=158–70 |date=March 2014 |pmid=24753638 |pmc=3993046 |doi= |url=}}</ref><ref name="pmid9803196">{{cite journal |vauthors=Ferrer R |title=Lymphadenopathy: differential diagnosis and evaluation |journal=Am Fam Physician |volume=58 |issue=6 |pages=1313–20 |date=October 1998 |pmid=9803196 |doi= |url=}}</ref><ref name="pmid12484692">{{cite journal |vauthors=Bazemore AW, Smucker DR |title=Lymphadenopathy and malignancy |journal=Am Fam Physician |volume=66 |issue=11 |pages=2103–10 |date=December 2002 |pmid=12484692 |doi= |url=}}</ref>
{{familytree/start |summary=Management of lymphadenopathy}}
{{familytree/start |summary=Management of lymphadenopathy}}
{{familytree | | | | | | | | | | Z01 | | | | | | | |Z01='''History'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; width: 20em; padding:1em;"><br><div style="float: left; text-align: left; width: 20em; padding:1em;">
{{familytree | | | | | | | | | | Z01 | | | | | | | |Z01='''History'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; width: 20em; padding:1em;"><br><div style="float: left; text-align: left; width: 20em; padding:1em;">
Line 80: Line 80:
{{familytree | |!| | |!| | | | | |!| |`| J01 | | J02 | |J01=Negative|J02=Positive}}
{{familytree | |!| | |!| | | | | |!| |`| J01 | | J02 | |J01=Negative|J02=Positive}}
{{familytree | |!| | |!| | | | | |!| | | | | | | |!| | | |}}
{{familytree | |!| | |!| | | | | |!| | | | | | | |!| | | |}}
{{familytree | K04 | | K05 | | | |!| | | | | | K03 | |K04=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ '''Treat'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; padding:1em;">with [[antibiotics]] if required and/ or symptomatic treatment<br>
{{familytree | K04 | | K05 | | | |!| | | | | | | K03 | |K04=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ '''Treat'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; padding:1em;">with [[antibiotics]] if required and/ or symptomatic treatment<br>
❑ For an untreatable or disease with residual symptoms counsel the [[patient]]<br>
❑ For an untreatable or disease with residual symptoms counsel the [[patient]]<br>
❑ Follow up for advancing or persistent [[lymphadenopathy|LAD]]|K05=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Treat'''<div class="mw-collapsible mw-collapsed"><br>
❑ Follow up for advancing or persistent [[lymphadenopathy|LAD]]|K05=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Treat'''<div class="mw-collapsible mw-collapsed"><br>
Line 89: Line 89:
❑ [[Autoimmunity#Treatments|Treatment of autoimmune disorders]]<br>
❑ [[Autoimmunity#Treatments|Treatment of autoimmune disorders]]<br>
❑ [[Tuberculosis medical therapy|Tuberculosis treatment]]<br>
❑ [[Tuberculosis medical therapy|Tuberculosis treatment]]<br>
❑ [[Cat scratch fever medical therapy|cat scratch disease treatment]]|K01=Low risk|K02=High risk|K03='''Treat'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; padding:1em;"><br>Surgical resection/ [[chemotherapy]]/ [[radiotherapy]]}}
❑ [[Cat scratch fever medical therapy|cat scratch disease treatment]]|K01=Low risk|K02=High risk|K03=Staging}}
{{familytree | | | | | | | | | | |!| | | | | |!|}}
{{familytree | | | | | | | | | | |!| | | | | | |!|!|}}
{{familytree | | | | | | |,|-|-|-|^|-|-|.| | |!|}}
{{familytree | | | | | | |,|-|-|-|^|-|-|.| | | |!|V01 |V01='''Treat'''<div class="mw-collapsible mw-collapsed"><div style="float: left; text-align: left; padding:1em;"><br>Surgical resection/ [[chemotherapy]]/ [[radiotherapy]]}}
{{familytree | | | | | | A01 | | | | | A02 | |!| | | |A01= Low risk<br> |A02=High risk}}
{{familytree | | | | | | A01 | | | | | A02 | | |!| | | |A01= Low risk<br> |A02=High risk}}
{{familytree | | | | | | |!| | | | | | |!| | |!|}}
{{familytree | | | | | | |!| | | | | | |!| | | |!| | | }}
{{familytree | | | | | | |!| | | | | | B01 |-|'| | B01=<div style="float: left; text-align: left; line-height: 150% ">Specific tests/ [[biopsy]]}}
{{familytree | | | | | | |!| | | | | | B01 |-|-|'| | B01=<div style="float: left; text-align: left; line-height: 150% ">Specific tests/ [[biopsy]]}}
{{familytree | | | | | | |!| | | | | | | | | }}
{{familytree | | | | | | |!| | | | | | | | }}
{{familytree | | |,|-|-|-|^|-|-|.| | | | | | | | L01=Treatment}}
{{familytree | | |,|-|-|-|^|-|-|.| | | | | | | | L01=Treatment}}
{{familytree | | C01 | | | | | | C02 | | | | | | | | |C01=Localized|C02=Generalized}}
{{familytree | | C01 | | | | | | C02 | | | | | | | | |C01=Localized|C02=Generalized}}
Line 114: Line 114:
{{familytree |!| | | |!| | | H01 | | H02 | | | | | | | | | |H01=Positive|H02=Negative }}
{{familytree |!| | | |!| | | H01 | | H02 | | | | | | | | | |H01=Positive|H02=Negative }}
{{familytree |!| | | |!| | | |!| | | |!| | | | | | | | | |}}
{{familytree |!| | | |!| | | |!| | | |!| | | | | | | | | |}}
{{familytree |!| | | |!| | | I01 | | I02 | | | | | | | | | |I01=Treatment|I02= Follow-up}}
{{familytree |!| | | |!| | | I01 | | I02 | | | | | | | | | |I01=Staging|I02= Follow-up}}
{{familytree |G01 | |!| | | | | | | | | | | | | | | | |G01=Biopsy}}
{{familytree |G01 | |!| | | | |!| | | | | | | | | | | |G01=Biopsy}}
{{familytree |!| | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree |!| | | |!| | | J01 | | | | | | | | | | | | | |J01=Treatment}}
{{familytree |)|-|-| Q01 | | | | | | | | | | | | | | | | | | Q01=Negative|}}
{{familytree |)|-|-| Q01 | | | | | | | | | | | | | | | | | | Q01=Negative|}}
{{familytree |!| | | | | | | | | | | | | | | | | | | | | |}}
{{familytree |!| | | | | | | | | | | | | | | | | | | | | |}}
{{familytree |`|-|-| X01 | | | | | | | | | | | | | | | | | | | | | |X01=Positive}}
{{familytree |`|-|-| X01 | | | | | | | | | | | | | | | | | | | | | |X01=Positive}}
{{familytree | | | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree | | | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree | | | | Y01 | | | | | | | | | | | | | | | | | Y01=Treatment}}
{{familytree | | | | Y01 | | | | | | | | | | | | | | | | | Y01=Staging}}
{{familytree | | | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree | | | | E01 | | | | | | | | | | | | | | | | | |E01=Treatment}}


{{familytree/end}}
{{familytree/end}}

Revision as of 14:14, 22 August 2020

The algorathmn illustrates the approach to management of lymphadenopathy[1][2][3][4]. Borrowed from:[5][6][7]

.
 
 
 
 
 
 
 
 
 
History

Patient age (specific demographic characteristics (age) of certain malignancies)
❑ Duration of lymphadenopathy (<2 weeks or >1 year without an increase in size has low malignant potential)
❑ Past medical history of underlying disease, suggestive of immunodeficiency, or recurrent infections
❑ Sexual history suggestive of infection transmission
❑ Family history of certain malignant disorders (breast cancer, or melanoma)
❑ Exposure to communicable infectious diseases/ travel to high-risk areas
❑ Environmental exposure such as UV (skin cancer risk)/ animals/ occupational exposure
❑ Social history such as tobacco use, alcohol use (head and neck cancers risk)
❑ Associated symptoms such as pain, fever, weight loss, anorexia, cough, or recurrent UTIs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical exam

Appearance of the patient
Cachexia or surgical scar marks demonstrating previous malignancy treatment

Vital signs

Temperature: High-grade / low-grade fever may demonstrate infection.
Heart rate: Tachycardia with regular pulse may demonstrate infection.
Respiratory rate: Tachypnea may demonstrate respiratory system involvement (infection\ metastasis).
Blood pressure: Chronic hypertension or hypotension (may indicate sepsis as a complication).
Oxygen saturation: may be low if the respiratory system is affected.

❑ HEENT
Cardiovascular examination
Respiratory examination
Gastrointestinal system exam includes oral examination, abdominal examination, and digital rectal exam.

Splenomegaly) may demonstrate IM, hodgkin's/ non-Hodgkin's lymphoma, and sarcoidosis

Extremities exam

❑ Skin exam: Evaluate for the lesions that indicate malignancy such as melanoma/ potential inoculation sites for germ such as traumatic lesions.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palpable lymph node

❑ Location: (Localized vs generalized)

❑ For nodes involving several groups of nodes; suspect malignancy.
❑ An enlarged node in a lymphatic rich region; suspect local disease.
❑ Associated red streaking, suspect lymphangitis.
❑ Left supraclavicular L.N (Virchow's nodes); suspect gastric carcinoma
❑ Right supraclavicular L.N, suspect intra-thoracic carcinoma

❑ Dimensions
The aforementioned dimensions are abnormal for a palpable lymph node but do not lead to the suspicion of a neoplasm.

supraclavicular, iliac, epitrochlear, and popliteal lymph nodes >0.5cm
Inguinal nodes > 1.5 cm
❑ Other area lymph nodes >1 cm

❑ Tenderness or pain:

❑ Suspect infection.
❑ A neoplastic node may also demonstrate pain due to hemorrhage associated with central necrosis or a brisk growing tumor.

❑ Consistency

❑ Hard on palpation; suspect chronic inflammation
❑ consistent- acute inflammation
❑ Stony-hard and painless nodes-metastatic cancer/ granuloma
❑ Firm and rubbery nodes- lymphoma
❑ Matted L.N suspect mycobacterium / sarcoidosis/ lymphoma / metastatic carcinoma)

❑ Mobility

❑ Freely movable; suspect infections and collagen vascular disease
❑ Fixed L.N to surrounding tissue; suspect malignancy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labs

CBC with differential
ESR
CMP
Peripheral smaer
LFTs

  • Labs may be required at a later stage pf diagnosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic of self-limiting or benign disease
Pharyngitis, URTI, conjunctivitis, cat-scratch disease, etc
 
Suggests infection/ serious infection
 
 
 
Unexplained
 
 
 
Suggests malignancy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
May require specific tests

❑ Throat swab

Sputum exam
 
Perform specific tests
 
 
 
Risk factors for malignancy
Family history, age, exposure, etc
 
 
 
Perform specific tests
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excisional biopsy
 
 
 
 
 
 
 
Positive
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative
 
Positive
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treat
with antibiotics if required and/ or symptomatic treatment

❑ For an untreatable or disease with residual symptoms counsel the patient

❑ Follow up for advancing or persistent LAD
 
 
 
 
 
 
 
 
 
 
 
 
Staging
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treat

Surgical resection/ chemotherapy/ radiotherapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk
 
 
 
 
High risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific tests/ biopsy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Localized
 
 
 
 
 
Generalized
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review history and clues suggesting malignancy
 
 
 
 
 
Review history and clues suggesting malignancy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observe 3-4 weeks
 
 
 
 
 
Specific tests such as CXR, ultrasound, CT, lab workup, biopsy

The US findings that help differentiate benign lAD from malignant include:
Benign: An isoechoic oviod shaped lesion with variable borders. High long axis/short axis ratio(L/S) of >2. A hilum is present with blood flow. Pulsatility index id <1.5.

Malignant: A hypoechoic round lesion with sharp borders. Low L/S ratio of <2. Hilum is absent with peripheral blood flow distribution.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Undiagnostic
 
 
Diagnostic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Progress/persists
 
Regress
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No follow-up
 
 
Biopsy
 
 
Treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging
 
Follow-up
 
 
 
 
 
 
 
 
 
Biopsy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1. Garg PK, Jain BK, Dubey IB, Sharma AK (2013). "Generalized lymphadenopathy: physical examination revisited". Ann Saudi Med. 33 (3): 298–300. doi:10.5144/0256-4947.2012.01.7.1525. PMC 6078537. PMID 22750769.
  2. Soldes OS, Younger JG, Hirschl RB (October 1999). "Predictors of malignancy in childhood peripheral lymphadenopathy". J. Pediatr. Surg. 34 (10): 1447–52. doi:10.1016/s0022-3468(99)90101-x. PMID 10549745.
  3. Ghirardelli ML, Jemos V, Gobbi PG (March 1999). "Diagnostic approach to lymph node enlargement". Haematologica. 84 (3): 242–7. PMID 10189390.
  4. Ramadas AA, Jose R, Varma B, Chandy ML (2017). "Cervical lymphadenopathy: Unwinding the hidden truth". Dent Res J (Isfahan). 14 (1): 73–78. doi:10.4103/1735-3327.201136. PMC 5356393. PMID 28348622.
  5. Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (March 2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  6. Ferrer R (October 1998). "Lymphadenopathy: differential diagnosis and evaluation". Am Fam Physician. 58 (6): 1313–20. PMID 9803196.
  7. Bazemore AW, Smucker DR (December 2002). "Lymphadenopathy and malignancy". Am Fam Physician. 66 (11): 2103–10. PMID 12484692.